NIH Seals Grant Reviews Behind Closed Virtual Doors
Published Date: 9/22/2025
Notice
Summary
The NIH’s Center for Scientific Review is holding several closed virtual meetings in November 2025 to review and decide on grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for important medical and scientific research. If you’re involved in these grant programs, mark your calendar for these key review dates!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Small-Business Grant Reviews (Nov 19–20)
If you are a small business applying to NIH, the Small Business review panel (Bioanalytical Chemistry, Biophysics, and Assay Development) will meet virtually November 19–20, 2025 to review and evaluate grant applications. The meetings are closed to the public under 5 U.S.C. 552b(c)(4) and (6) to protect confidential trade secrets and personal information.
Fellowship Review Panel (Nov 19–20)
If you applied for NIH fellowships (for example, the Infectious Diseases and Immunology fellowships), the review panel will meet virtually November 19–20, 2025 to review and evaluate fellowship grant applications. The meetings are closed to the public to protect confidential and personal information.
Multiple NIH Grant Panels Scheduled (Nov 19–20)
Several NIH Center for Scientific Review panels (including cancer drug development, pathway to research independence, aging/neurological/behavioral health topics, biomedical informatics, and others) will meet virtually on November 19 and November 19–20, 2025 to review and evaluate grant applications. These meetings are closed under 5 U.S.C. 552b(c)(4) and (6) to protect confidential trade secrets and personal information.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-18273, Advancing the Development of Pediatric Therapeutics (ADEPT) 10: Addressing Challenges in Neonatal Product Development-Leveraging Rare Disease Frameworks; Public Meeting
The FDA is hosting a public workshop to tackle tough problems in making medicines for newborn babies, especially by using ideas from rare disease treatments. This meeting helps drug makers, doctors, and families work together to speed up safe, effective treatments for tiny patients. It’s a big step toward better care for newborns, with chances to save time and money in developing new medicines.
Next: 2025-18275, Clinical Center; Notice of Closed Meeting
The NIH Clinical Center’s Board of Scientific Counselors is holding a private virtual meeting on October 20-21, 2025, to review grant applications and discuss staff performance. This closed meeting protects personal privacy while deciding who gets funding and support. If you want to share your thoughts, you can send written comments before the meeting.